176 related articles for article (PubMed ID: 26176330)
21. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
22. The KDEL receptor, ERD2, regulates intracellular traffic by recruiting a GTPase-activating protein for ARF1.
Aoe T; Cukierman E; Lee A; Cassel D; Peters PJ; Hsu VW
EMBO J; 1997 Dec; 16(24):7305-16. PubMed ID: 9405360
[TBL] [Abstract][Full Text] [Related]
23. Correct targeting of plant ARF GTPases relies on distinct protein domains.
Matheson LA; Suri SS; Hanton SL; Chatre L; Brandizzi F
Traffic; 2008 Jan; 9(1):103-20. PubMed ID: 17988226
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of ADP-ribosylation factor 1 in human gastric carcinoma and its clinicopathological significance.
Tsai MM; Lin PY; Cheng WL; Tsai CY; Chi HC; Chen CY; Tseng YH; Cheng YF; Chen CD; Liang Y; Liao CJ; Wu SM; Lin YH; Chung IH; Wang CS; Lin KH
Cancer Sci; 2012 Jun; 103(6):1136-44. PubMed ID: 22348287
[TBL] [Abstract][Full Text] [Related]
26. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
27. ARF1 regulates the Rho/MLC pathway to control EGF-dependent breast cancer cell invasion.
Schlienger S; Campbell S; Claing A
Mol Biol Cell; 2014 Jan; 25(1):17-29. PubMed ID: 24196838
[TBL] [Abstract][Full Text] [Related]
28. The phosphatase of regenerating liver 3 (PRL-3) promotes cell migration through Arf-activity-dependent stimulation of integrin α5 recycling.
Krndija D; Münzberg C; Maass U; Hafner M; Adler G; Kestler HA; Seufferlein T; Oswald F; von Wichert G
J Cell Sci; 2012 Aug; 125(Pt 16):3883-92. PubMed ID: 22595524
[TBL] [Abstract][Full Text] [Related]
29. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
30. ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer.
Zhang Y; Bi J; Zhu H; Shi M; Zeng X
Biosci Biotechnol Biochem; 2018 Oct; 82(10):1733-1741. PubMed ID: 29912633
[TBL] [Abstract][Full Text] [Related]
31. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
32. Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.
Lang L; Shay C; Zhao X; Teng Y
J Exp Clin Cancer Res; 2017 Aug; 36(1):112. PubMed ID: 28830537
[TBL] [Abstract][Full Text] [Related]
33. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
35. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
36. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
[TBL] [Abstract][Full Text] [Related]
37. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
Tyagi A; Agarwal R; Agarwal C
Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
39. ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling.
Davis JE; Xie X; Guo J; Huang W; Chu WM; Huang S; Teng Y; Wu G
Oncotarget; 2016 Jun; 7(26):39834-39845. PubMed ID: 27213581
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
